Early clinical studies to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of sergliflozin, a novel inhibitor of renal glucose reabsorption, in healthy volunteers and subjects with type 2 diabetes mellitus

被引：0
|
作者：
Hussey, Elizabeth K.
Clark, Richard V.
Amin, Dipti M.
Kipnes, Mark S.
O'Connor-Semmes, Robin L.
O'Driscoll, Eilis C.
Leong, Jenny
Murray, Sharon C.
Dobbins, Robert L.
Nunez, Derek J.
机构：
来源：
DIABETES | 2007年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A49 / A49
页数：1
相关论文
共 50 条
  • [31] Safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of the dipeptidyl peptidase 4 inhibitor BI 1356 (proposed tradename ONDERO) in healthy Japanese volunteers
    Sesoko, Shogo
    Nakajima, Mitsuyoshi
    Hayashi, Naoyuki
    Sarashina, Akiko
    Taniguchi, Atushi
    Horie, Yoshiharu
    Dugi, Klaus A.
    DIABETES, 2008, 57 : A159 - A159
  • [32] A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of DS-3801b, a Motilin Receptor Agonist, in Healthy Subjects
    Dennie, Justin
    Atiee, George
    Warren, Vance
    Tao, Ben
    Morimoto, Kiyoshi
    Senaldi, Giorgio
    JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (09): : 1221 - 1230
  • [33] First-in-Human, Single-Ascending Dose and Food Effect Studies to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Cetagliptin, a Dipeptidyl Peptidase-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
    Wang, Lu
    Lu, Jinmiao
    Zhou, Sufeng
    Zhao, Yuqing
    Xie, Lijun
    Zhou, Chen
    Chen, Juan
    Ding, Sijia
    Xie, Daosheng
    Ding, Juping
    Yu, Qiang
    Shen, Hong
    Hao, Guangtao
    Shao, Feng
    CLINICAL DRUG INVESTIGATION, 2021, 41 (11) : 999 - 1010
  • [34] First-in-Human, Single-Ascending Dose and Food Effect Studies to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Cetagliptin, a Dipeptidyl Peptidase-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
    Lu Wang
    Jinmiao Lu
    Sufeng Zhou
    Yuqing Zhao
    Lijun Xie
    Chen Zhou
    Juan Chen
    Sijia Ding
    Daosheng Xie
    Juping Ding
    Qiang Yu
    Hong Shen
    Guangtao Hao
    Feng Shao
    Clinical Drug Investigation, 2021, 41 : 999 - 1010
  • [35] A first in human, single ascending dose study to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of AB101 in subjects with type 1 diabetes
    Roberts, B. K.
    Wang, X.
    Franey, B.
    Hernandez, M.
    Hompesch, M.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 73 - 73
  • [36] Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of Youkenafil Hydrochloride, a Phosphodiesterase Type 5 Inhibitor, in Healthy Chinese Male Volunteers
    Liang, Beibei
    Wang, Jin
    Bai, Nan
    Chi, Yulong
    Wang, Rui
    Cai, Yun
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022, 11 (10): : 1184 - 1190
  • [37] Population Pharmacokinetics of Metformin in Healthy Subjects and Patients with Type 2 Diabetes Mellitus: Simulation of Doses According to Renal Function
    Duong, Janna K.
    Kumar, Shaun S.
    Kirkpatrick, Carl M.
    Greenup, Louise C.
    Arora, Manit
    Lee, Toong C.
    Timmins, Peter
    Graham, Garry G.
    Furlong, Timothy J.
    Greenfield, Jerry R.
    Williams, Kenneth M.
    Day, Richard O.
    CLINICAL PHARMACOKINETICS, 2013, 52 (05) : 373 - 384
  • [38] Population Pharmacokinetics of Metformin in Healthy Subjects and Patients with Type 2 Diabetes Mellitus: Simulation of Doses According to Renal Function
    Janna K. Duong
    Shaun S. Kumar
    Carl M. Kirkpatrick
    Louise C. Greenup
    Manit Arora
    Toong C. Lee
    Peter Timmins
    Garry G. Graham
    Timothy J. Furlong
    Jerry R. Greenfield
    Kenneth M. Williams
    Richard O. Day
    Clinical Pharmacokinetics, 2013, 52 : 373 - 384
  • [39] Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus
    Kasichayanula, S.
    Chang, M.
    Hasegawa, M.
    Liu, X.
    Yamahira, N.
    LaCreta, F. P.
    Imai, Y.
    Boulton, D. W.
    DIABETES OBESITY & METABOLISM, 2011, 13 (04): : 357 - 365
  • [40] Crossover Dose Escalation Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of Single Doses of R1663, an Oral Factor Xa Inhibitor, in Healthy Male Volunteers
    Schmitt, Christophe
    Pannier, Anne
    McIntyre, Christine
    Zandt, Hagen
    Ciorciaro, Cornelia
    Winters, Katie
    Pepper, Tom
    JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (04): : 499 - 510
12345